



#4



U.S. APPLICATION NO

United States Patent and Trademark Office

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231 www.uspto.gov

ATTY. DOCKET NO.

09/674377	NAKAMURA	T Q 61434						
		INTERNATIONAL APPLICATION NO.						
SUGHRUE MION ZINN MACPEAK 2100 PENNSYLVANIA AVENUE NV	· -	PCT/JP99/01834						
WASHINGTON, DC 20037 3202		I.A. FILING DATE PRIORITY DATE						
		06 APR 99 28 APR 98						
!	1	DATE MAILED: 17 MAY 2001						
NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)								
1. The following items have been submi								
	(37 CFR 1.494) an Elected Office Indication of Small En	e (37 CFR 1.495):						
Oath or Declaration of inven Copy of Article 19 amendme	tors(s). Translation of Article	tion of Article 19 amendments into English.						
Priority Document. The International Preliminary	y Examination Report in English and its	s Annexes, if any.						
Translation of Annexes to the	e International Preliminary Examination	n Report into English.						
	The Basic National Fee and the copy	not filed the following indicated items and/or of the international application must be filed mal application.						
3. The following items MUST be furnish acceptance under 35 U.S.C. 371:	-							
	ion into English. A processing fee will							
	te 20 or 30 months from the priority da is defective for the reasons indicated or							
b. Processing fee for providi	ng the translation of the application and onths from the priority date (37 CFR 1	.492(f)).						
the application (prefera surcharge will be requi	inventors, in compliance with 37 CFR bly by the International application num red if submitted later than the appropria	ber and international filing date). A						
date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.								
	ne oath or declaration later than the app	ropriate 20 or 30 months from the						
priority date (37 CFR 1.492(e)). 4. Additional claim fees of \$ as a large entity small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.								
5. Applicant has not submitted the rec PCT/DO/EO/920.	quired sequence listing pursuant to 37 C	FR 1.821-1.825. See attached						
ALL OF THE ITEMS SET FORTH IN	IS NOTICE OR BY 22 OR 32 MONT PLICATION, WHICHEVER IS LAT	THS (where 37 CFR 1.495 applies) FROM						
The time period set above may be extend 1.136(a).	ed by filing a petition and fee for exten	sion of time under the provisions of 37 CFR						
Annexes will be cancelled. A processing	fee will be required if submitted later ancelled since a translation was not prov	no later than the time period set above or the than 20 or 30 months from the priority date. ided by the appropriate 20 (37 CFR 1.494(d))						
Applicant is reminded that any communic address given in the heading and include								
A copy of this Enclosed: PCT/DO/EO/917	notice MUST be returned							
= PTO-875	PCT/DO/EO/920	ONDA WALLACE /U/						
FORM PCT/DO/EO/905 (March 2001)		703 305-3736						

FIRST NAMED APPLICANT





UNITED STATES PATENT AND TRADEMARK OFFICE

#4/A

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

U.S. APPLICATION NO.		FIRST NAMED APPLICANT				ATTY. DOCKET NO.	
09/674377			NAKAMURA	Т		Q 61434	
					INTERNATIONAL APPLICATION NO.		
SUGHRUE MION ZINN MACPEAK & SEAS 2100 PENNSYLVANIA AVENUE NW			PCT/JP99/01834				
WASHINGTON, DC 20037 3202			1.A	. FILING DATE	PRIORITY DATE		
				06	APR 99	28 APR 98	
				-	7	7 MAY 2006	

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL:

are the same and, where applicable, include no new matter, as required by 37 CFR

(703) 308-4216, for Rules interpretation,

(703) 308-4212, for CRF submission help,

1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

(703) 287-0200, for PatentIn software help.

VONDA WALLACE /. VI

FORM PCT/DO/EO/920 (March 2001)